Craig Thompson is the Chief Executive Officer of Cerevance, a private, clinical-stage biotechnology company focused on next-generation neurodegenerative medicines using cell-type specific targeted approaches. Mr. Thompson brings over 25 years of commercial and marketing leadership experience in the biotech and pharmaceutical industries to Cerevance. Prior to joining Cerevance, Mr. Thompson served as President and CEO at Neurana Pharmaceuticals, a private company focused on the treatment of neuromuscular conditions, and was also a member of their board of directors. Prior to Neurana, he served as President and CEO of Anthera Pharmaceuticals, and before that, as COO of Tetraphase Pharmaceuticals, where he oversaw the development and implementation of the marketing, access, reimbursement, and sales strategy, as well as business development and commercial manufacturing. Prior to Tetraphase, he was chief commercial officer at Trius Therapeutics, which was acquired by Cubist Pharmaceuticals for more than $700 million. Earlier in his career, Mr. Thompson served in various commercial and marketing roles of increasing responsibility at large commercial pharmaceutical companies, including Pfizer and Merck. Mr. Thompson holds a bachelor’s degree in commerce from McMaster University and an MBA from the University of Notre Dame.
.svg)
